 | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌvɪsmoʊˈdɛɡɪb/ VIS-moh-DEG-ib |
| Trade names | Erivedge |
| Other names | GDC-0449, RG-3616 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 31.8% |
| Protein binding | >99% |
| Metabolism | <2% metabolised byCYP2C9,CYP3A4,CYP3A5 |
| Eliminationhalf-life | 4 days (continuous use), 12 days (single dose) |
| Excretion | Fecal (82%), Urinary (4.4%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.234.019 |
| Chemical and physical data | |
| Formula | C19H14Cl2N2O3S |
| Molar mass | 421.29 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vismodegib, sold under the brand nameErivedge, is amedication used for the treatment ofbasal-cell carcinoma (BCC).[3] The approval of vismodegib on January 30, 2012, represents the firstHedgehog signaling pathway targeting agent to gain U.S.Food and Drug Administration (FDA) approval.[4] The drug is also undergoing clinical trials for metastaticcolorectal cancer,small-cell lung cancer, advancedstomach cancer,pancreatic cancer,medulloblastoma andchondrosarcoma as of June 2011[update].[5] The drug was developed by thebiotechnology/pharmaceutical companyGenentech.[4]
Vismodegib isindicated for people withbasal-cell carcinoma (BCC) which has metastasized to other parts of the body, relapsed after surgery, or cannot be treated with surgery or radiation.[4][6]
The substance acts as acyclopamine-competitiveantagonist of thesmoothened receptor (SMO) which is part of theHedgehog signaling pathway.[5] SMO inhibition causes the transcription factorsGLI1 andGLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway.[7] This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.[8]
In clinical trials, commonside effects included gastrointestinal disorders (nausea, vomiting, diarrhoea, constipation), muscle spasms, fatigue, hair loss, anddysgeusia (distortion of the sense of taste).[3]
Vismodegib has undergone several promisingphase I andphase II clinical trials for its use in treating medulloblastoma.[9]
